DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Vinorelbine

First Posted Date: 2020-03-13

Last Posted Date: 2020-03-13

Lead Sponsor: Fudan University

Target Recruit Count: 316

Registration Number: NCT04307147

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: SHR-1316
Drug: Bevacizumab
Drug: Cisplatin/Carboplatin

First Posted Date: 2020-03-11

Last Posted Date: 2024-07-18

Lead Sponsor: Fudan University

Target Recruit Count: 35

Registration Number: NCT04303988

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Capecitabine

First Posted Date: 2020-03-10

Last Posted Date: 2020-03-10

Lead Sponsor: Fudan University

Target Recruit Count: 550

Registration Number: NCT04302441

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Camrelizumab
Combination Product: US/CT-guided Percutaneous Cryoablation

First Posted Date: 2020-03-09

Last Posted Date: 2025-02-27

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04299581

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Capecitabine
Drug: Trastuzumab

First Posted Date: 2020-03-05

Last Posted Date: 2025-04-17

Lead Sponsor: Fudan University

Target Recruit Count: 178

Registration Number: NCT04296162

Locations: 🇨🇳
Zhi-Ming Shao, Shanghai, China

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

Phase 3

Active, not recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: ddEpirubicin
Drug: Epirubicin
Drug: CTX
Drug: ddCTX
Drug: Paclitaxel(with carbo)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2020-03-05

Last Posted Date: 2025-03-26

Lead Sponsor: Fudan University

Target Recruit Count: 808

Registration Number: NCT04296175

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sintilimab
Combination Product: TACE

First Posted Date: 2020-03-05

Last Posted Date: 2025-02-27

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04297280

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2020-03-05

Last Posted Date: 2022-07-22

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04297267

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

Not Applicable

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Diagnostic Test: TCHP

First Posted Date: 2020-02-24

Last Posted Date: 2020-05-04

Lead Sponsor: Fudan University

Target Recruit Count: 94

Registration Number: NCT04281641

Locations: 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China

Next-generation Sequencing of Colorectal Cancer Somatic Cells to Guide Genetic Susceptibility Gene Mutations Screening.

Conditions: Hereditary Colorectal Cancer

First Posted Date: 2020-02-21

Last Posted Date: 2020-02-21

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04280666

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy